Percutaneous transluminal septal myocardial ablation: past, present, and future
Yuichiro Maekawa1, Itaru Takamisawa2, Hitoshi Takano3
1Internal Medicine III, Division of Cardiology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Insights
Percutaneous transluminal septal myocardial ablation (PTSMA) reduces left ventricular outflow tract pressure gradients in hypertrophic obstructive cardiomyopathy (HOCM). Advancements in imaging improve treatment selection for HOCM patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Imaging
Background:
- Hypertrophic obstructive cardiomyopathy (HOCM) affects a significant portion of hypertrophic cardiomyopathy patients.
- Left ventricular outflow tract pressure gradient (LVOT PG) is a key feature of HOCM.
- Drug-refractory HOCM with heart failure necessitates effective treatment strategies.
Purpose of the Study:
- To review the efficacy and challenges of Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) for HOCM.
- To highlight the role of imaging advancements in improving treatment decisions for HOCM.
- To discuss the comparative effectiveness of PTSMA and surgical myectomy (SM).
Main Methods:
- Percutaneous transluminal septal myocardial ablation (PTSMA) using ethanol to ablate septal myocardium.
- Myocardial contrast echocardiography (MCE)-guided PTSMA as a standard technique.
- Utilizing cardiac computed tomography and magnetic resonance imaging to clarify LVOT obstruction mechanisms.
Main Results:
- PTSMA effectively reduces LVOT PG and improves heart failure symptoms in HOCM patients.
- MCE-guided PTSMA is widely adopted globally.
- Operator and institutional experience significantly impact PTSMA outcomes.
Conclusions:
- PTSMA is a valuable treatment for symptomatic, drug-refractory HOCM.
- Predicting PTSMA response remains a challenge.
- Advanced imaging facilitates better selection between PTSMA and surgical myectomy (SM), improving patient prognosis.
Abstract:
About 30% of patients with hypertrophic cardiomyopathy have a significant left ventricular pressure gradient at rest, and 60%-70% of these patients are diagnosed with hypertrophic obstructive cardiomyopathy (HOCM) because an induced pressure gradient is also present. Percutaneous transluminal septal myocardial ablation (PTSMA) is a procedure in which ethanol is used to ablate the portion of the septal myocardium that is involved in the pathogenesis of the left ventricular outflow tract pressure gradient (LVOT PG). In 1995, Sigwart et al. reported three cases of PTSMA in The Lancet. The introduction of PTSMA into clinical practice has enabled the reduction of LVOT PG and improvement of heart failure symptoms in elderly and high-risk patients with symptomatic, drug-refractory HOCM. In 1998, Faber et al. published a report in Circulation on selective septal myocardial ablation using myocardial contrast echocardiography (MCE). MCE-guided PTSMA is now recognized as the standard method of PTSMA in many countries and regions, including Europe, North America, and Asia, and is estimated to be performed on about 300 to 400 patients per year in Japan based on reports from the Japanese Circulation Society's Clinical Practice Survey. The current problems with this technique are: 1) the outcome is greatly influenced by operators' and institutional experience, and 2) it is difficult to determine in advance whether the patient is a PTSMA responder or not. Recently, advancements in imaging modalities, including cardiac computed tomography and magnetic resonance imaging, have facilitated clarification of the mechanisms of LVOT obstruction. Therefore, more appropriate decisions regarding PTSMA and surgical myectomy (SM) are now made. Better treatment selection will undoubtedly improve the prognosis of patients with drug-refractory HOCM complicated by heart failure, and further elucidation of the pathogenesis of LVOT obstruction and technical advances in PTSMA and SM are eagerly awaited.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
